APA (7th ed.) Citation

MA, D., VTM, H., A, R., S, D., G, M., T, M., . . . K, W. (2023). Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): A phase 3, open-label, randomised study. The Lancet. Haematology, 10(10), e801. https://doi.org/10.1016/S2352-3026(23)00243-0

Chicago Style (17th ed.) Citation

MA, Dimopoulos, et al. "Efficacy and Safety of Single-agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (DREAMM-3): A Phase 3, Open-label, Randomised Study." The Lancet. Haematology 10, no. 10 (2023): e801. https://doi.org/10.1016/S2352-3026(23)00243-0.

MLA (9th ed.) Citation

MA, Dimopoulos, et al. "Efficacy and Safety of Single-agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (DREAMM-3): A Phase 3, Open-label, Randomised Study." The Lancet. Haematology, vol. 10, no. 10, 2023, p. e801, https://doi.org/10.1016/S2352-3026(23)00243-0.